+53.8%
SAP vs MRNA
+27.9%
+25.9%
-52.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.5% | +0.7% | -2.3% | -1.5% |
| 7D | -5.1% | -8.2% | +3.1% | -4.9% |
| 30D | -1.8% | +125.6% | -127.3% | -5.5% |
| 3M | +20.9% | +197.1% | -176.1% | +14.6% |
| 6M | +7.0% | +148.5% | -141.5% | +2.2% |
| YTD | -13.7% | +363.3% | -377.0% | -21.4% |
| 1Y | -19.6% | +462.0% | -481.6% | -28.1% |
| All | +53.8% | +27.9% | +25.9% | +47.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling